Ligand Pharmaceuticals Completes Merger, Launches Pelthos Therapeutics as Publicly Traded Company
I'm PortAI, I can summarize articles.
Ligand Pharmaceuticals Inc. has completed its merger with LNHC, Inc. and CHRO Merger Sub Inc., forming Pelthos Therapeutics Inc., which will trade on the NYSE American under the ticker symbol "PTHS" starting July 2, 2025. Pelthos plans to launch ZELSUVMI, a treatment for Molluscum contagiosum infections, in July 2025. Ligand has invested $18 million in the new entity and will receive a 13% royalty on worldwide sales of ZELSUVMI.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments